- Charles River Laboratories Announces Strategic Lentiviral Vector Manufacturing Collaboration with Gates Institute at University of Colorado Anschutz Medical Campus
- Charles River and Captain T Cell Announce Plasmid DNA and Viral Vector Manufacturing Alliance for Gene-Modified Cell Therapy
- Charles River Laboratories, in Collaboration With MatTek Corporation, Awarded Grant from the Foundation for Chemistry Research and Initiatives to Advance Research Alternatives
- Charles River Laboratories Expands Access to CRADL® Contract Vivarium Space in Somerville
- Charles River Laboratories Announces Development of Nonclinical Virtual Control Groups with Sanofi to Reduce the Use of Animals in Research
- Charles River Laboratories to Present at William Blair and Jefferies Conferences
- Charles River Launches Viral Vector Tech Transfer Program to Safeguard Gene Therapy Development
- Charles River Laboratories Announces First-Quarter 2024 Results
- Charles River Launches Viral Vector Reference Materials to Streamline the Transition to GMP
- Charles River Laboratories Achieves 100% Renewable Electricity Usage Globally
More ▼
Key statistics
On Tuesday, Charles River Laboratories International Inc (CRL:NYQ) closed at 201.48, 24.64% above the 52 week low of 161.65 set on Nov 01, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 203.10 |
---|---|
High | 204.10 |
Low | 201.09 |
Bid | 180.00 |
Offer | 246.00 |
Previous close | 201.48 |
Average volume | 443.60k |
---|---|
Shares outstanding | 51.51m |
Free float | 51.00m |
P/E (TTM) | 23.64 |
Market cap | 10.38bn USD |
EPS (TTM) | 8.52 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 00:00 BST.
More ▼